公开(公告)号：US08691209B2

公开(公告)日：2014-04-08

申请号：US13294006

申请日：2011-11-10

申请人： Martin F. Bachmann ,  Tazio Storni ,  Patrik Maurer ,  Alain Tissot ,  Katrin Schwarz ,  Edwin Meijerink ,  Gerd Lipowsky ,  Paul Pumpens ,  Indulis Cielens ,  Regina Renhofa

发明人： Martin F. Bachmann ,  Tazio Storni ,  Patrik Maurer ,  Alain Tissot ,  Katrin Schwarz ,  Edwin Meijerink ,  Gerd Lipowsky ,  Paul Pumpens ,  Indulis Cielens ,  Regina Renhofa

IPC分类号： A01N63/00 ,  C12N1/20 ,  C12N7/00

CPC分类号： A61K39/12 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/02 ,  A61K39/39 ,  A61K2039/52 ,  A61K2039/5258 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/57 ,  A61K2039/6075 ,  C07K14/005 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/22022 ,  C12N2710/22023 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2795/00034 ,  C12N2795/18122 ,  Y02A50/412 ,  Y02A50/467

摘要： The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

摘要翻译： 本发明涉及病毒样颗粒（VLP）可以加载免疫刺激物质，特别是含有非甲基化C和G（CpG）的DNA寡核苷酸的发现。 这样的CpG-VLP比其不含CpG的对应物显着地更具免疫原性，并诱导增强的B和T细胞应答。 与抗VLP本身的免疫应答相似地，抗体任选偶联，融合或附着于VLP的抗原的免疫应答也被增强。 此外，针对VLP和抗原的T细胞应答特别针对Th1型。 因此，连接到CpG负载的VLP的抗原可能是针对过敏，肿瘤和其他自身分子和慢性病毒性疾病的预防性或治疗性接种疫苗的理想疫苗。

公开(公告)号：US20120301499A1

公开(公告)日：2012-11-29

申请号：US13294006

申请日：2011-11-10

申请人： MARTIN BACHMANN ,  TAZIO STORNI ,  PATRIK MAURER ,  ALAIN TISSOT ,  KATRIN SCHWARZ ,  EDWIN MEIJERINK ,  GERD LIPOWSKY ,  PAUL PUMPENS ,  INDULIS CIELENS ,  REGINA RENHOFA

发明人： MARTIN BACHMANN ,  TAZIO STORNI ,  PATRIK MAURER ,  ALAIN TISSOT ,  KATRIN SCHWARZ ,  EDWIN MEIJERINK ,  GERD LIPOWSKY ,  PAUL PUMPENS ,  INDULIS CIELENS ,  REGINA RENHOFA

IPC分类号： A61K39/385 ,  A61P31/12 ,  C12P19/34 ,  A61P33/00 ,  A61P35/00 ,  A61P37/08 ,  A61K35/76 ,  A61P31/04

CPC分类号： A61K39/12 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/02 ,  A61K39/39 ,  A61K2039/52 ,  A61K2039/5258 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/57 ,  A61K2039/6075 ,  C07K14/005 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/22022 ,  C12N2710/22023 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2795/00034 ,  C12N2795/18122 ,  Y02A50/412 ,  Y02A50/467

摘要： The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

摘要翻译： 本发明涉及病毒样颗粒（VLP）可以加载免疫刺激物质，特别是含有非甲基化C和G（CpG）的DNA寡核苷酸的发现。 这样的CpG-VLP比其不含CpG的对应物显着地更具免疫原性，并诱导增强的B和T细胞应答。 与抗VLP本身的免疫应答相似地，抗体任选偶联，融合或附着于VLP的抗原的免疫应答也被增强。 此外，针对VLP和抗原的T细胞应答特别针对Th1型。 因此，连接到CpG负载的VLP的抗原可能是针对过敏，肿瘤和其他自身分子和慢性病毒性疾病的预防性或治疗性接种疫苗的理想疫苗。

公开(公告)号：US20060182793A1

公开(公告)日：2006-08-17

申请号：US10565264

申请日：2004-07-22

申请人： Martin Bachmann ,  Vania Manolova ,  Tazio Storni

发明人： Martin Bachmann ,  Vania Manolova ,  Tazio Storni

IPC分类号： A61K48/00 ,  A61K9/127

CPC分类号： A61K39/39 ,  A61K9/127 ,  A61K2039/55555 ,  A61K2039/55561 ,  Y02A50/412

摘要： Liposomes are known to enhance the activity of K- (B-) type CpGs which trigger the production of IL-12. In the present invention, the surprising finding was made that liposomes also enhance the activity of D- (A-) type CpGs, leading to the production of IFNα in vivo. These findings are relevant for the humans situation, since IFNα rather than IL-12 is the key cytokine for the induction of Th1 responses and anti-viral protection in humans.

摘要翻译： 已知脂质体可增强触发IL-12产生的K-（B-）型CpG的活性。 在本发明中，令人惊奇的发现是，脂质体还增强D-（A-）型CpG的活性，导致体内IFNα的产生。 这些发现与人类情况相关，因为IFNalpha而不是IL-12是人类Th1应答诱导和抗病毒保护的关键细胞因子。

公开(公告)号：US20090074851A1

公开(公告)日：2009-03-19

申请号：US12171876

申请日：2008-07-11

申请人： Martin F. BACHMANN ,  Vania Manolova ,  Tazio Storni

发明人： Martin F. BACHMANN ,  Vania Manolova ,  Tazio Storni

IPC分类号： A61K9/127 ,  A61K31/7088 ,  A61P43/00

CPC分类号： A61K39/39 ,  A61K9/127 ,  A61K2039/55555 ,  A61K2039/55561 ,  Y02A50/412

摘要： Liposomes are known to enhance the activity of K- (B-) type CpGs which trigger the production of IL-12. In the present invention, the surprising finding was made that liposomes also enhance the activity of D- (A-) type CpGs, leading to the production of IFNα in vivo. These findings are relevant for the humans situation, since IFNα rather than IL-12 is the key cytokine for the induction of Th1 responses and anti-viral protection in humans.

摘要翻译： 已知脂质体可增强触发IL-12产生的K-（B-）型CpG的活性。 在本发明中，令人惊奇的发现是，脂质体还增强D-（A-）型CpG的活性，导致体内IFNα的产生。 这些发现与人类情况相关，因为IFNalpha而不是IL-12是人类Th1应答诱导和抗病毒保护的关键细胞因子。